Takara Bio Inc. (4974.T)
JPY 824.0
(0.37%)
JPY 824.0
(0.37%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 788 Million JPY | -4.02% |
| 2022 | 821 Million JPY | -9.78% |
| 2021 | 910 Million JPY | -9.27% |
| 2020 | 1 Billion JPY | 1.72% |
| 2019 | 986 Million JPY | 0.0% |
| 2018 | - JPY | 0.0% |
| 2017 | - JPY | -100.0% |
| 2016 | 82 Million JPY | -36.92% |
| 2015 | 130 Million JPY | -26.97% |
| 2014 | 178 Million JPY | -20.89% |
| 2013 | 225 Million JPY | -17.58% |
| 2012 | 273 Million JPY | -18.51% |
| 2011 | 335 Million JPY | -7.97% |
| 2010 | 364 Million JPY | -11.22% |
| 2009 | 410 Million JPY | -9.89% |
| 2008 | 455 Million JPY | -9.18% |
| 2007 | 501 Million JPY | -8.24% |
| 2006 | 546 Million JPY | -7.46% |
| 2005 | 590 Million JPY | -57.71% |
| 2004 | 1.39 Billion JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - JPY | 0.0% |
| 2023 Q1 | - JPY | -100.0% |
| 2023 FY | 788 Million JPY | -4.02% |
| 2023 Q3 | - JPY | 0.0% |
| 2023 Q4 | 788 Million JPY | 0.0% |
| 2023 Q2 | - JPY | 0.0% |
| 2022 Q4 | 821 Million JPY | 0.0% |
| 2022 Q2 | - JPY | 0.0% |
| 2022 Q1 | - JPY | -100.0% |
| 2022 FY | 821 Million JPY | -9.78% |
| 2022 Q3 | - JPY | 0.0% |
| 2021 Q1 | - JPY | -100.0% |
| 2021 Q2 | - JPY | 0.0% |
| 2021 Q3 | - JPY | 0.0% |
| 2021 FY | 910 Million JPY | -9.27% |
| 2021 Q4 | 910 Million JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 FY | 1 Billion JPY | 1.72% |
| 2020 Q1 | - JPY | -100.0% |
| 2020 Q4 | 1 Billion JPY | 0.0% |
| 2019 Q4 | 986 Million JPY | 0.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2019 FY | 986 Million JPY | 0.0% |
| 2019 Q2 | - JPY | 0.0% |
| 2019 Q1 | - JPY | 0.0% |
| 2018 Q4 | - JPY | 0.0% |
| 2018 Q3 | - JPY | 0.0% |
| 2018 FY | - JPY | 0.0% |
| 2018 Q2 | - JPY | 0.0% |
| 2018 Q1 | - JPY | 0.0% |
| 2017 Q3 | 82 Million JPY | -86.71% |
| 2017 Q2 | 617 Million JPY | 3.52% |
| 2017 Q1 | 596 Million JPY | 626.83% |
| 2017 FY | - JPY | -100.0% |
| 2017 Q4 | - JPY | -100.0% |
| 2016 Q2 | 116 Million JPY | -10.77% |
| 2016 Q3 | 116 Million JPY | 0.0% |
| 2016 FY | 82 Million JPY | -36.92% |
| 2016 Q1 | 130 Million JPY | 0.0% |
| 2016 Q4 | 82 Million JPY | -29.31% |
| 2015 Q3 | 164 Million JPY | 0.0% |
| 2015 Q1 | 178 Million JPY | 0.0% |
| 2015 FY | 130 Million JPY | -26.97% |
| 2015 Q2 | 164 Million JPY | -7.87% |
| 2015 Q4 | 130 Million JPY | -20.73% |
| 2014 Q3 | 211 Million JPY | 0.0% |
| 2014 Q2 | 211 Million JPY | -6.22% |
| 2014 Q1 | 225 Million JPY | 0.0% |
| 2014 Q4 | 178 Million JPY | -15.64% |
| 2014 FY | 178 Million JPY | -20.89% |
| 2013 FY | 225 Million JPY | -17.58% |
| 2013 Q2 | 258 Million JPY | -5.49% |
| 2013 Q1 | 273 Million JPY | 0.0% |
| 2013 Q4 | 225 Million JPY | -12.79% |
| 2013 Q3 | 258 Million JPY | 0.0% |
| 2012 Q3 | 309 Million JPY | -1.28% |
| 2012 Q1 | 332 Million JPY | -0.9% |
| 2012 Q2 | 313 Million JPY | -5.72% |
| 2012 Q4 | 273 Million JPY | -11.65% |
| 2012 FY | 273 Million JPY | -18.51% |
| 2011 Q3 | 350 Million JPY | 0.0% |
| 2011 Q4 | 335 Million JPY | -4.29% |
| 2011 Q1 | 364 Million JPY | 0.0% |
| 2011 FY | 335 Million JPY | -7.97% |
| 2011 Q2 | 350 Million JPY | -3.85% |
| 2010 Q2 | 396 Million JPY | -3.41% |
| 2010 Q4 | 364 Million JPY | -8.08% |
| 2010 Q3 | 396 Million JPY | 0.0% |
| 2010 Q1 | 410 Million JPY | 0.0% |
| 2010 FY | 364 Million JPY | -11.22% |
| 2009 Q3 | 441 Million JPY | 0.0% |
| 2009 FY | 410 Million JPY | -9.89% |
| 2009 Q4 | 410 Million JPY | -7.03% |
| 2009 Q2 | 441 Million JPY | 0.0% |
| 2008 Q4 | 455 Million JPY | 0.0% |
| 2008 FY | 455 Million JPY | -9.18% |
| 2007 FY | 501 Million JPY | -8.24% |
| 2006 FY | 546 Million JPY | -7.46% |
| 2005 FY | 590 Million JPY | -57.71% |
| 2004 FY | 1.39 Billion JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 767.03 Million JPY | -2.733% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 2 Billion JPY | 60.6% |
| Linical Co., Ltd. | 1.49 Billion JPY | 47.465% |
| Trans Genic Inc. | 1.32 Billion JPY | 40.621% |
| MEDINET Co., Ltd. | 781 Thousand JPY | -100796.287% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.34 Billion JPY | 66.426% |
| AnGes, Inc. | 214.94 Million JPY | -266.599% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | -637.489% |
| Nxera Pharma Co., Ltd. | 63.21 Billion JPY | 98.753% |
| Immuno-Biological Laboratories Co., Ltd. | 84.56 Million JPY | -831.872% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 28.94% |
| Carna Biosciences, Inc. | 28.4 Million JPY | -2674.453% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 875.59 Million JPY | 10.004% |
| RaQualia Pharma Inc. | 39.05 Million JPY | -1917.926% |
| Chiome Bioscience Inc. | - JPY | -Infinity% |
| Kidswell Bio Corporation | 1.83 Billion JPY | 57.126% |
| PeptiDream Inc. | 19.63 Billion JPY | 95.987% |
| Oncolys BioPharma Inc. | 161.1 Million JPY | -389.137% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 397 Million JPY | -98.489% |
| Healios K.K. | 450 Million JPY | -75.111% |
| BrightPath Biotherapeutics Co., Ltd. | - JPY | -Infinity% |
| Kubota Pharmaceutical Holdings Co., Ltd. | - JPY | -Infinity% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 77.29 Million JPY | -919.524% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 773.29 Million JPY | -1.902% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 491.35 Million JPY | -60.374% |
| StemCell Institute Inc. | 6.67 Million JPY | -11703.475% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 143.75 Million JPY | -448.174% |